{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:00:11Z","timestamp":1763564411723,"version":"3.40.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01795-7","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:13:54Z","timestamp":1746188034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlation between total prostate specific antigen and histological grading of prostate cancer in Kenyan mission hospital: a five-year retrospective review"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1606-7985","authenticated-orcid":false,"given":"Chinonso Paul","family":"Shu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0838-2352","authenticated-orcid":false,"given":"Marius J.","family":"Tchinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsamayem Georter James","family":"Sop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0938-4513","authenticated-orcid":false,"given":"Signang Alberic","family":"Ndonku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Irungu","family":"Juma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"3","key":"1795_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1795_CR2","doi-asserted-by":"crossref","unstructured":"Giona S. The Epidemiology of Prostate Cancer. In: Bott SR, Ng KL, editors. Prostate Cancer [Internet]. Brisbane (AU): Exon Publications; 2021. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK571326\/","DOI":"10.36255\/exonpublications.prostatecancer.epidemiology.2021"},{"issue":"5","key":"1795_CR3","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u2013386.","journal-title":"Int J Cancer"},{"issue":"3","key":"1795_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.juro.2014.04.017","volume":"192","author":"AW Hsing","year":"2014","unstructured":"Hsing AW, Yeboah E, Biritwum R, Tettey Y, De Marzo AM, Adjei A, et al. High prevalence of screen detected prostate cancer in West Africans: implications for Racial disparity of prostate cancer. J Urol. 2014;192(3):730\u20135.","journal-title":"J Urol"},{"issue":"4","key":"1795_CR5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/S0022-5347(01)64966-8","volume":"157","author":"DN Osegbe","year":"1997","unstructured":"Osegbe DN. Prostate cancer in Nigerians: facts and nonfacts. J Urol. 1997;157(4):1340\u20133.","journal-title":"J Urol"},{"issue":"1","key":"1795_CR6","first-page":"6","volume":"28","author":"RO Ahmed","year":"2022","unstructured":"Ahmed RO, Sewram V, Oyesegun AR, Ayele B, van Wyk A, Fernandez P. A comparison of clinicopathologic features of prostate cancer between Nigerian and South African black men. Afr J Urol Off J Pan Afr Urol Surg Assoc PAUSA. 2022;28(1):6.","journal-title":"Afr J Urol Off J Pan Afr Urol Surg Assoc PAUSA"},{"issue":"4\u20135","key":"1795_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.14740\/wjon1221","volume":"10","author":"A Cassell","year":"2019","unstructured":"Cassell A, Yunusa B, Jalloh M, Mbodji MM, Diallo A, Ndoye M, et al. A review of localized prostate cancer: an African perspective. World J Oncol. 2019;10(4\u20135):162\u20138.","journal-title":"World J Oncol"},{"issue":"4","key":"1795_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2298\/ACI0704105M","volume":"54","author":"B Milkovic","year":"2007","unstructured":"Milkovic B, Hadzi-Djokic J, Dzamic Z, Pejcic T. The significance of TPSA, free to total PSA ratio and PSA density in prostate carcinoma diagnostics. Acta Chir Iugosl. 2007;54(4):105\u20137.","journal-title":"Acta Chir Iugosl"},{"key":"1795_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2016.00123","volume":"7","author":"G Facchini","year":"2016","unstructured":"Facchini G, Caffo O, Ortega C, D\u2019Aniello C, Di Napoli M, Cecere SC, et al. Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor predicting overall survival. Front Pharmacol. 2016;7:123.","journal-title":"Front Pharmacol"},{"issue":"1 Pt 1","key":"1795_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jfma.2021.02.015","volume":"121","author":"CY Huang","year":"2022","unstructured":"Huang CY, Chen CH. Clinical characteristics and survival outcomes in patients with a high PSA and non-metastatic prostate cancer. J Formos Med Assoc Taiwan Yi Zhi. 2022;121(1 Pt 1):181\u20136.","journal-title":"J Formos Med Assoc Taiwan Yi Zhi"},{"issue":"4","key":"1795_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0022-5347(17)38972-3","volume":"142","author":"MA Hudson","year":"1989","unstructured":"Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol. 1989;142(4):1011\u20137.","journal-title":"J Urol"},{"key":"1795_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.11604\/pamj.2018.30.240.14000","volume":"30","author":"GI Ogbole","year":"2018","unstructured":"Ogbole GI, Adeyomoye AO, Badu-Peprah A, Mensah Y, Nzeh DA. Survey of magnetic resonance imaging availability in West Africa. Pan Afr Med J. 2018;30:240.","journal-title":"Pan Afr Med J"},{"issue":"15","key":"1795_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1056\/NEJM198710083171501","volume":"317","author":"TA Stamey","year":"1987","unstructured":"Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909\u201316.","journal-title":"N Engl J Med"},{"key":"1795_CR14","doi-asserted-by":"publisher","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer incidence and mortality: global status and Temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.","journal-title":"Front Public Health"},{"key":"1795_CR15","doi-asserted-by":"crossref","unstructured":"Carlsson SV, Murata K, Danila DC, Lilja H. PSA: role in screening and monitoring patients with prostate cancer. In: Cancer Biomarkers [Internet]. Elsevier; 2022. pp. 131\u201372. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128243022000011","DOI":"10.1016\/B978-0-12-824302-2.00001-1"},{"issue":"3","key":"1795_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2298\/AOO0403148Z","volume":"12","author":"S Zivkovic","year":"2004","unstructured":"Zivkovic S. Correlation between prostate-specific antigen and histopathological difference of prostate carcinoma. Arch Oncol. 2004;12(3):148\u201351.","journal-title":"Arch Oncol"},{"issue":"1","key":"1795_CR17","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3126\/jpn.v9i1.23376","volume":"9","author":"S Pudasaini","year":"2019","unstructured":"Pudasaini S, Subedi N, Shrestha NM. Evaluation of prostate specific antigen levels and its correlation with histopathological findings. J Pathol Nepal. 2019;9(1):1485\u20139.","journal-title":"J Pathol Nepal"},{"issue":"5","key":"1795_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4103\/jcrt.jcrt_1719_21","volume":"19","author":"E Rani","year":"2023","unstructured":"Rani E, Nibhoria S, Nagpal N. Outlook of Gleason score in prostate carcinoma and correlation with PSA levels: A study in a tertiary care hospital. J Cancer Res Ther. 2023;19(5):1305\u201310.","journal-title":"J Cancer Res Ther"},{"issue":"6","key":"1795_CR19","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0022-5347(17)35302-8","volume":"151","author":"M Aihara","year":"1994","unstructured":"Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate Cancer. J Urol. 1994;151(6):1558\u201364.","journal-title":"J Urol"},{"issue":"2","key":"1795_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/1117-1936.170330","volume":"18","author":"CC Anunobi","year":"2011","unstructured":"Anunobi CC, Akinde OR, Elesha SO, Daramola AO, Tijani KH, Ojewola RW. Prostate diseases in Lagos, Nigeria: a histologic study with tPSA correlation. Niger Postgrad Med J. 2011;18(2):98\u2013104.","journal-title":"Niger Postgrad Med J"},{"issue":"3","key":"1795_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1464-410X.2006.06650.x","volume":"99","author":"M May","year":"2007","unstructured":"May M, Kaufmann O, Hammermann F, Loy V, Siegsmund M. Prognostic impact of lymphovascular invasion in radical prostatectomy specimens. BJU Int. 2007;99(3):539\u201344.","journal-title":"BJU Int"},{"issue":"13","key":"1795_CR22","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1245\/s10434-011-1790-4","volume":"18","author":"JH Jung","year":"2011","unstructured":"Jung JH, Lee JW, Arkoncel FRP, Cho NH, Yusoff NAM, Kim KJ, et al. Significance of perineural invasion, lymphovascular invasion, and High-Grade prostatic intraepithelial neoplasia in Robot-Assisted laparoscopic radical prostatectomy. Ann Surg Oncol. 2011;18(13):3828\u201332.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1795_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000020256","volume":"38","author":"A De La Taille","year":"2000","unstructured":"De La Taille A, Rubin MA, Buttyan R, Olsson CA, Bagiella E, Burchardt M, et al. Is microvascular invasion on radical prostatectomy specimens a useful predictor of PSA recurrence for prostate Cancer patients?? Eur Urol. 2000;38(1):79\u201384.","journal-title":"Eur Urol"},{"issue":"2","key":"1795_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.eururo.2005.10.027","volume":"49","author":"SF Shariat","year":"2006","unstructured":"Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10ng\/ml. Eur Urol. 2006;49(2):293\u2013302.","journal-title":"Eur Urol"},{"issue":"S7","key":"1795_CR25","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/1097-0142(19950401)75:7+<1842::AID-CNCR2820751614>3.0.CO;2-2","volume":"75","author":"PA Humphrey","year":"1995","unstructured":"Humphrey PA, Baty J, Keetch D. Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. Cancer. 1995;75(S7):1842\u20139.","journal-title":"Cancer"},{"key":"1795_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/modpathol.2017.167","volume":"31","author":"DJ Grignon","year":"2018","unstructured":"Grignon DJ. Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens. Mod Pathol. 2018;31:96\u2013109.","journal-title":"Mod Pathol"},{"key":"1795_CR27","doi-asserted-by":"publisher","first-page":"1349536","DOI":"10.3389\/fonc.2024.1349536","volume":"14","author":"J Karwacki","year":"2024","unstructured":"Karwacki J, \u0141\u0105tkowska M, Jarocki M, Jaworski A, Szuba P, Poterek A, et al. The clinical meaning of lymphovascular invasion: preoperative predictors and postoperative implications in prostate cancer - a retrospective study. Front Oncol. 2024;14:1349536.","journal-title":"Front Oncol"},{"issue":"6","key":"1795_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0090-4295(99)00350-7","volume":"54","author":"A De La Taille","year":"1999","unstructured":"De La Taille A, Katz A, Bagiella E, Olsson CA, O\u2019Toole KM, Rubin MA. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology. 1999;54(6):1039\u201343.","journal-title":"Urology"},{"issue":"4","key":"1795_CR29","doi-asserted-by":"publisher","first-page":"888","DOI":"10.5604\/12321966.1129953","volume":"21","author":"W Szot","year":"2014","unstructured":"Szot W, Kostkiewicz M, Zaj\u0105c J, Owoc A, Bojar I. Prostate cancer in patients from rural and suburban areas \u2013 PSA value, Gleason score and presence of metastases in bone scan. Ann Agric Environ Med. 2014;21(4):888\u201392.","journal-title":"Ann Agric Environ Med"},{"issue":"1","key":"1795_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0009-9120(98)00088-5","volume":"32","author":"W Li","year":"1999","unstructured":"Li W, Ren Y, Mee V, Wong PY. Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer. Clin Biochem. 1999;32(1):31\u20137.","journal-title":"Clin Biochem"},{"issue":"1","key":"1795_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/(SICI)1097-0045(19990615)40:1<56::AID-PROS7>3.0.CO;2-E","volume":"40","author":"W Horninger","year":"1999","unstructured":"Horninger W, Rogatsch H, Reissigl A, Volgger H, Klocker H, Hobisch A, et al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening. Prostate. 1999;40(1):56\u201361.","journal-title":"Prostate"},{"issue":"3\u20134","key":"1795_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11255-006-6672-5","volume":"38","author":"AA Elabbady","year":"2007","unstructured":"Elabbady AA, Khedr MM. Free\/total PSA ratio can help in the prediction of high Gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3\u201310 Ng\/ml. Int Urol Nephrol. 2007;38(3\u20134):553\u20137.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"1795_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0022-5347(17)40079-6","volume":"143","author":"AW Partin","year":"1990","unstructured":"Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143(4):747\u201352.","journal-title":"J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01795-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:13:59Z","timestamp":1746188039000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01795-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1795"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01795-7","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We obtained ethical clearance from the Kijabe Hospital Institutional Scientific and Ethical Review Committee (REF: KH\/ISERC\/0036\/2023). Data collection sheets were anonymized. All methods were performed by ethical guidelines as stipulated in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declaration"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}